Editor: Elísio Costa

Erythropoietic Stimulating Agents

Volume 1

eBook: US $89 Special Offer (PDF + Printed Copy): US $163
Printed Copy: US $119
Library License: US $356
ISSN: 2542-7350 (Print)
ISSN: 2214-6210 (Online)
ISBN: 978-1-60805-748-1 (Print)
ISBN: 978-1-60805-747-4 (Online)
Year of Publication: 2013
DOI: 10.2174/97816080574741130101

Introduction

The development of new erythropoietic stimulating agents (ESAs) has significantly increased in recent years. Researchers are focused on different and interesting concepts, namely, methods to increase half-life of erythropoietin (EPO), finding different routes of administration and new ESA or modified EPO molecules. Scientific literature presents evidence that EPO has other effects beyond erythropoietic stimulation. These pleiotropic effects of EPO appear to result from the existence of two different EPO receptors (EPOR) with different affinities for EPO. The discovery of new EPO actions beyond the hematopoietic system has opened a new field of investigation with these agents. Several molecules have been developed to present the protective action, without the activation of the hematopoietic system. These agents can be potentially used in several diseases of the brain/central and peripheral nervous system, eye, heart and kidney.

This volume of Frontiers in Drug Discovery includes a revision of articles on erythropoiesis and EPO gene regulation, microRNAs and their potential contribution to the development of new therapeutic strategies, animal models for studying kidney disease-associated anemia as well as benefits/risks of ESA therapy. The biological effects of new ESA molecules, heparin-binding erythropoietin and of pHBSP, and the potential applications of ESA, are also elicited in this volume.

This volume is, therefore, a useful reference for medicinal chemists and hematologists interested in drug development and medicine related to ESAs.

Contributors

Editor(s):
Elísio Costa
Faculty of Pharmacy of University of Porto
Institute for Molecular and Cellular Biology of University of Porto
Portugal
/
nstitute for Molecular and Cellular
Biology of University of Porto
Portugal




Co-Editor(s):
Flávio Reis
Laboratory of Pharmacology and Experimental Therapeutics
IBILI, Faculty of Medicine of University of Coimbra
Portugal


Alice Santos-Silva
Faculty of Pharmacy of University of Porto
Institute for Molecular and Cellular Biology of University of Porto
Portugal




Contributor(s):
Alice Santos-Silva
Faculty of Pharmacy of University of Porto and
Institute for Molecular and Cellular Biology of University of Porto
Portugal


Ana Cabrita
Nephrology Department
Hospital de Faro
Portugal


Ana P. Silva
Nephrology Department
Hospital de Faro
Portugal


Casper Hempel
Centre for Medical Parasitology at Department of Clinical Microbiology and Department of Infectious Diseases
Copenhagen University Hospital (Rigshospitalet) and Department of International Health
Immunology and Microbiology, University of Copenhagen
Denmark


Christoph Thiemermann
Barts and the London School of Medicine and Dentistry
The William Harvey Research Institute, Queen Mary University of London
UK


Elísio Costa
Faculty of Pharmacy of University of Porto and Institute for Molecular
Cellular Biology of University of Porto
Portugal


Elsa Bronze-da-Rocha
Faculty of Pharmacy of University of Porto and Institute for Molecular
Cellular Biology of University of Porto
Portugal


Flávio Reis
Laboratory of Pharmacology and Experimental Therapeutics
IBILI, Faculty of Medicine of University of Coimbra
Portugal


Gabriela R. Dincheva
Department of Surgery, Division of Cardiac Surgery
Albert Einstein College of Medicine-Beth Israel Medical Center
New York
USA


Heiko Sorg
Department of Plastic, Hand and Reconstructive Surgery
Hannover Medical School
Germany


I. Michael Leitman
Department of Surgery, Division of Cardiac Surgery
Albert Einstein College of Medicine-Beth Israel Medical Center
New York
USA


Idalina Beirão
Nephrology Department, Santo António General Hospital
UMIB, Abel Salazar Biomedical Sciences Institute, University of Porto
Porto
Portugal


João C. Fernandes
IBILI, Faculty of Medicine of University of Coimbra
Institute for Molecular and Cellular Biology of University of Porto
and Laboratory of Pharmacology and Experimental Therapeutics
Portugal


Jørgen A.L. Kurtzhals
Centre for Medical Parasitology at Department of International Health
Immunology and Microbiology, University of Copenhagen and Department of Clinical Microbiology
Copenhagen University Hospital
Denmark


Kamellia R. Dimitrova
Department of Surgery, Division of Cardiac Surgery
Albert Einstein College of Medicine-Beth Israel Medical Center
New York
USA


Ken Toba
Department of Hematology
Niigata University Medical and Dental Hospital
Niigata
Japan


Kiran K. Nandra
The William Harvey Research Institute, Barts and The London School of Medicine and Dentistry
Queen Mary University of London
UK


Masato Moriyama
Department of Hematology
Niigata University Medical and Dental Hospital
Niigata
Japan


Matti Aapro
Multidisciplinary Oncology Institute
Clinique de Genolier
Genolier
Switzerland


Nimesh S.A. Patel
The William Harvey Research Institute
Barts and The London School of Medicine and Dentistry
Queen Mary University of London
UK


Patrícia Garrido
Laboratory of Pharmacology and Experimental Therapeutics
IBILI, Faculty of Medicine of University of Coimbra
Portugal


Paulo P. Costa
Portugal and Genetics Department
UMIB, Abel Salazar Biomedical Sciences Institute, University of Porto
INSA Dr. Ricardo Jorge
Porto
Portugal


Pedro L. Neves
Nephrology Department
Hospital de Faro
Portugal


Peter M. Vogt
Department for Plastic
Hand and Reconstructive Surgery, Hannover Medical School
Hannover
Germany


Reto Wettstein
Department of Plastic, Reconstructive and Aesthetic Surgery
University Hospital of Basel and Department of Plastic, University Hospital of Lausanne
Lausanne
Switzerland


Sandra Ribeiro
Faculty of Pharmacy of University of Porto
Institute for Molecular and Cellular Biology of University of Porto
Portugal


Steve Elliott
Department of Hematology/Oncology, Amgen Inc
Institute of Physiology, University of Lübeck
Lübeck, Germany
Thousand Oaks
CA
USA


Susana Coimbra
Institute for Molecular and Cellular Biology of University of Porto
Polytechnic Health Institute of the North – Cooperative Higher Education
Polytechnic and University
Gandra-Paredes
Portugal


Wolfgang Jelkmann
Department of Hematology/Oncology, Amgen Inc.
Institute of Physiology, University of Lübeck, Lübeck, Germany
Thousand Oaks
CA
USA


Yves Harder
Department of Plastic Surgery Inselspital University Hospital
Berne
Switzerland




RELATED BOOKS

.Anti-Angiogenesis Drug Discovery and Development.
.Bioactive Phytochemicals: Drug Discovery to Product Development.
.Angiogenesis & Therapeutic Targets In Cancer.
.Anti-Angiogenesis Drug Discovery and Development   .